| abstract |
Aspects of the present disclosure relate to local delivery of pentaaza macrocyclic ring complexes to the intestines and methods of using the same. Certain disclosed dosage forms, including oral dosage forms suitable for local delivery and characterized by low systemic oral bioavailability, are therapeutically effective to relieve symptoms of inflammatory diseases of the lower gastrointestinal tract (e.g. small intestine, colon, and/or rectum) while minimizing systemic toxicity. |